Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Press releases

May 31, 2023 | REGULATORY

Change in number of shares and votes in Immunovia AB (publ)

Read press release
May 26, 2023 | REGULATORY

Bulletin from the Annual General Meeting in Immunovia AB

Read press release
May 23, 2023 | REGULATORY

Immunovia Publishes Interim Report for January-March 2023

Read press release
May 22, 2023 | REGULATORY

Changes to the Nomination Committee’s proposal to the Annual General Meeting 2023 in Immunovia AB (publ)

Read press release
May 17, 2023

Invitation to Immunovia’s Q1 presentation

Read press release
May 6, 2023 | REGULATORY

The board member Philipp von Hugo resigns from Immunovia’s board at his own request

Read press release
April 29, 2023 | REGULATORY

Immunovia AB appoints new CEO

Read press release
April 26, 2023

Immunovia to discuss adoption of IMMrayTM PanCan-d with key opinion leaders on May 3, 2023

Read press release
April 25, 2023 | REGULATORY


Read press release
April 21, 2023 | REGULATORY

Immunovia publishes the annual report for 2022

Read press release
April 20, 2023

Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer

Read press release
April 12, 2023 | REGULATORY

Immunovia announces outcome of the rights issue

Read press release
1 2 3 4 5 28